Rashad Iskandrni 

 

When a child is born with "dwarfism" or what is medically known as "achondroplasia," the challenge goes beyond short stature; it extends to unseen daily details, such as a child’s inability to perform basic life tasks at home, or struggling to access educational and professional environments due to a stature that halts at the 120-centimeter mark.

For decades, medical options available for dwarfism were limited to supportive care and complication management. However, a historic turning point occurred in 1994, when research teams successfully identified the root genetic cause of the condition: a specific dominant mutation in the fibroblast growth factor receptor 3 "FGFR3" gene on the short arm of chromosome 4. This discovery led to an understanding of the condition's anatomical mechanism, shifting medical research away from external surgical solutions toward the innovation of biological protocols designed to disable this genetic "brake" from within.

Recent years have witnessed an exceptional research breakthrough, culminating in the transition from laboratory studies to clinical application through the development of drugs targeted at inhibiting the negative signaling resulting from the "FGFR3" mutation. This restores the natural balance of chondrocyte proliferation and differentiation, establishing an entirely new phase in protecting children from long-term motor and developmental complications.

Commenting on the latest updates regarding achondroplasia treatments, Dr. Talal S. Al-Anzi, Consultant in Genetics and Metabolism at Johns Hopkins Aramco Healthcare in Dhahran and a member of the Saudi Society of Medical Genetics, noted that the new treatments represent a beacon of hope for families of children with dwarfism. This is especially true after observing tangible developmental and motor improvements in cases that underwent these treatments, making them the most successful alternative compared to previous medical options that yielded negligible results.

Dr. Talal Al-Anzi stated with a tone filled with hope: "We have seen families filled with optimism, and we have observed significant motor and developmental improvements in children... This improvement is not merely numbers on a height scale; rather, it is a targeted molecular intervention in a gene called "FGFR3"  that gives the affected child a golden opportunity to grow to a stature approaching the average height of their family members."

Al-Anzi explained that the window for treatment is tied to skeletal flexibility before growth centers close, emphasizing that early intervention in the first or second year gives the child an opportunity to reach a final adult height close to that of their family members.

The genetics consultant outlined the approved scientific steps to reach treatment, which include genetic screening to verify the presence of a mutation in the "FGFR3" gene responsible for the impairment of long bone growth in the limbs. Regarding the treatment method, Al-Anzi explained that it consists of a single daily injection administered subcutaneously, continuing daily until bone growth is complete.

Al-Anzi praised Saudi Arabia's medical readiness, noting that new treatments for "achondroplasia" are already available in leading centers in Saudi Arabia, where a large number of diagnosed patients are currently undergoing active treatment.

In concluding his remarks, the member of the Saudi Society of Medical Genetics emphasized the profound social and economic impact of providing these treatments, as they help protect children from challenges that could hinder their life path and the realization of their full potential, thereby ensure their full integration and empower them to make genuine, productive contributions to their societies.